O-GlcNAcylation of GLI transcription factors in hyperglycemic conditions augments Hedgehog activity

• Published in: Laboratory investigation Vol. 99; no. 2; pp. 260 - 270
• Main Authors: Das, Shamik, Bailey, Sarah K., Metge, Brandon J., Hanna, Ann, Hinshaw, Dominique C., Mota, Mateus, Forero-Torres, Andres, Chatham, John C., Samant, Rajeev S., Shevde, Lalita A.
• Format: Journal Article
• Language: English
• Published: New York Elsevier Inc 01.02.2019; Nature Publishing Group US; Nature Publishing Group
• Subjects: 13/95; 38/77; 42/109; 631/67/1347; 631/80/458; 631/80/86/2368; 96/106; Acetylglucosamine - metabolism; Angiogenesis; Breast cancer; Cancer; Carrier Proteins - metabolism; Cell Line, Tumor; Cell survival; Chemoresistance; Drug resistance; ERCC1 protein; Glucose; Glucose - metabolism; Glycolysis; Hedgehog Proteins - metabolism; Humans; Hyperglycemia; Intermediates; Laboratory Medicine; Medicine; Medicine & Public Health; Membrane Proteins - metabolism; Metastases; N-Acetylglucosamine; N-Acetylglucosaminyltransferases - metabolism; O-GlcNAcylation; Pathology; Proteins; Thyroid Hormone-Binding Proteins; Thyroid Hormones - metabolism; Transcription factors; Transcription Factors - metabolism; XRCC1 protein
• ISSN: 0023-6837; 1530-0307
• DOI: 10.1038/s41374-018-0122-8

Modification of proteins by O-linked β-N-acetylglucosamine (O-GlcNAc) promotes tumor cell survival, proliferation, epigenetic changes, angiogenesis, invasion, and metastasis. Here we demonstrate that in conditions of elevated glucose, there is increased expression of key drug resistance proteins (ABCB1, ABCG2, ERCC1, and XRCC1), all of which are regulated by the Hedgehog pathway. In elevated glucose conditions, we determined that the Hedgehog pathway transcription factors, GLI1 and GLI2, are modified by O-GlcNAcylation. This modification functionally enhanced their transcriptional activity. The activity of GLI was enhanced when O-GlcNAcase was inhibited, while inhibiting O-GlcNAc transferase caused a decrease in GLI activity. The metabolic impact of hyperglycemic conditions impinges on maintaining PKM2 in the less active state that facilitates the availability of glycolytic intermediates for biosynthetic pathways. Interestingly, under elevated glucose conditions, PKM2 directly influenced GLI activity. Specifically, abrogating PKM2 expression caused a significant decline in GLI activity and expression of drug resistance proteins. Cumulatively, our results suggest that elevated glucose conditions upregulate chemoresistance through elevated transcriptional activity of the Hedgehog/GLI pathway. Interfering in O-GlcNAcylation of the GLI transcription factors may be a novel target in controlling cancer progression and drug resistance of breast cancer. Under hyperglycemic conditions, there is aberrant activation of the Hedgehog pathway due to increased O-GlcNAcylation of the GLI1 and GLI2 transcription factors; this modification enhances their transcriptional activity. This study lays a foundation for inhibiting O-GlcNAcylation, particularly in cancer patients with diabetes or metabolic disease, in order to control metabolism, progression and/or drug resistance of breast cancer.